Loading clinical trials...
Loading clinical trials...
This study will be a single subject study to evaluate the efficacy of the HER2 kinase inhibitor, neratinib, in a patient with metastatic bladder cancer harboring a HER2-GRB7 gene fusion.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
NCT07124000 · Adenocarcinoma (NOS), Anal Cancer, and more
NCT06682728 · Urothelial Carcinoma, Muscle-invasive Bladder Cancer
NCT06814496 · Melanoma, Medullary Thyroid Cancer, and more
NCT06257264 · Breast Cancer, Small Cell Lung Cancer, and more
NCT07206225 · Non-muscle Invasive Bladder Cancer
North Carolina Cancer Hospital (UNC)
Chapel Hill, North Carolina
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions